Business News • PR NewsWire • BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease

BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease

BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease

National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 RESEARCH TRIANGLE PARK, N.C. and PARIS, Aug. 23, 2022 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and...

View More : https://www.prnewswire.com:443/news-releases/brainvectis-a-subsidiary-of-askbio-receives-clearance-to-conduct-phase-iii-...

Releted News by prnewswire

Barge Transportation Market Size to Grow by USD 32.74 Billion, Rising Crude Oil Movement by Barges to Drive Growth - Technavio

Sciatica Treatment Market Size to Grow by USD 2.52 billion, Rising Awareness about Sciatica to Boost Market Growth - Technavio

Vaderis Therapeutics AG sort de l'ombre et annonce le lancement d'un essai clinique de preuve de concept portant sur la THH

BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease

Wemade Holds the 1st Anniversary Event of MIR4 Global Service!

BerGenBio reports second quarter and half year 2022 financial results and provides business update

Akumina Positioned as the Leader in the 2022 SPARK Matrix for Intranet Platform Providers by Quadrant Knowledge Solutions